KMT2A and acute myeloid leukemia: In this study, we investigate the ability of azacitidine, a DNA hypomethylating agent, and panobinostat, a histone deacetylase inhibitor, to overcome endothelial, stromal, and MSC-induced chemoprotection in pediatric AML samples with KMT2A rearrangement.